GovChime
Notice ID: 405fffae1e9645fe9e08f0f2c398666eSpecial Notice

Human Monoclonal Antibody (mAb) Development for Walter Reed Army Institute of Research (WRAIR), Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS)

Archived on May 15, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM UTC−04:00
Posted
April 15, 2024
Notice type
Special Notice
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
ARMY MED RES ACQ ACTIVITY
Place of performance
Silver Spring, MD, 20901
Last updated
Dec 4, 2025

Identifiers

Solicitation number
HT942524Q0057
Notice ID
405fffae1e9645fe9e08f0f2c398666e

Description

The U.S. Army Medical Research Acquisition Activity (USAMRAA) in support of the Walter Reed Army Institute of Research (WRAIR) Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS) intends to negotiate solely (as prescribed in FAR 13.106(b)(1)(i)) with Genovac Antibody Discovery, LLC located at 1810 NDSU Research Circle N, Suite B, Fargo, ND 58102 to perform feasibility studies for the development and production of a panel of fully human mAbs for AFRIMS-supplied target antigens or using AFRIMS-supplied cultured B cells for use in developing immunotherapeutic against bacterial pathogens associated with wound infection and sepsis. This shall include immunization in transgenic animal model expressing fully human Immunoglobulin G (IgG) antibodies, high-throughput single-cell screening for antigen-specific Antibody-Secreting Cells (ASCs) and cloning and expression of recombinant mAbs for two (2) years. The North American Industry Classification System (NAICS) for this requirement is 541714 and the size standard is 1,000. This announcement constitutes the only notice by the government; a written solicitation will not be issued. All sources that believe they are eligible to provide these items must respond in writing. Responses must be supported with clear and convincing evidence to clearly articulate the ability to provide the items outlined above. A request for documentation will not be considered an affirmative response. This Special Notice of Intent is not a request for competitive quotes. Information received will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government. If no written responses are received by the date listed below, the purchase will be awarded without further remark. All questions and responses concerning this notice shall be emailed to Ms. Flodean Billings at flodean.p.billings.civ@health.mil. Interested concerns must identify their capability in writing to the above e-mail address or by mail to the address listed below no later than 10:00 am ET, 30 April 2024. Contracting Office Address: US Army Medical Research Acquisition Activity, ATTN: FCMR-ACO-AA, 808 Schreider Street, Frederick, MD 21702-5014. Point of Contact: Flodean Billings 301-619-2648 flodean.p.billings.civ@health.mil.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:HT942524Q0057
  1. Special NoticeCurrentApr 15, 2024

    Human Monoclonal Antibody (mAb) Development for Walter Reed Army Institute of Research (WRAIR), Armed Forces Research Institute of Medical Sciences (WRAIR-AFRIMS)

    Notice 405fffae1e9645fe9e08f0f2c398666e on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

HT942524Q0057

Archive Date

May 15, 2024

Office Address

FORT DETRICK, MD, 21702